Socioeconomic and Treatment Factors Affect Non-Hodgkin Lymphoma Patients’ Survival

Publication
Article
OncologyONCOLOGY Vol 22 No 12
Volume 22
Issue 12

Socioeconomic factors and the type of treatment received have an impact on a non-Hodgkin lymphoma (NHL) patient’s risk of dying.

Socioeconomic factors and the type of treatment received have an impact on a non-Hodgkin lymphoma (NHL) patient’s risk of dying. That is the finding of a new study to be published in the December 1, 2008 issue of Cancer. The study reveals that poorer socioeconomic status increases a patient’s risk of dying, while receiving chemotherapy reduces the risk.

NHL is common in the elderly. Its incidence has been increasing over the past several decades, and Caucasians have higher incidence and death rates related to the disease than patients in other ethnic groups. Newer treatments for NHL have become available in recent years; however, studies have not addressed ethnic disparities in survival as they relate to treatment, diagnosis, socioeconomic status, or other factors.

To investigate the issue, Xianglin Du, md, of the University of Texas School of Public Health in Houston and colleagues analyzed Surveillance, Epidemiology and End Results (SEER)-Medicare linked data for more than 13,000 patients diagnosed at age 65 or older between 1992 and 1999.

Dr. Du and his team analyzed data related to survival, socioeconomic status, treatment (chemotherapy or radiation), tumor factors (stage and type of NHL), the presence of other diseases or conditions, and other characteristics such as age, race, marital status, and geographic area.

The investigators found that receiving chemotherapy was associated with prolonged survival in patients with NHL and that elderly Caucasian patients with NHL were more likely to receive chemotherapy (52.4%) compared with African-Americans (43.2%). Also, poor socioeconomic status was significantly associated with increased risk of mortality, and there were a larger proportion of African-American patients living in poor communities compared with other ethnicities. No significant differences in the risk of death were seen between African-Americans and Caucasians after controlling for factors such as treatment and socioeconomic status.

Recent Videos
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Related Content